 |
 |
 |
 |
 |
 |
||||
 |
About IQuum: Management Team | |
||
|
 |
 |
|
|
|
Management Team |
 |
IQuum's team of scientific and business experts is committing its knowledge, experience, and energy to build the biological analysis systems of the future.
Management Bios Shuqi Chen, Ph.D., is President, CEO, and Chairman of the Board. He is the founder of IQuum, and a former Harvard faculty member. IQuum's intellectual property is based on his vision and innovative approach to biological sample processing and testing that has been in development since 1994. Dr. Chen has a Ph.D. in Medicine, an M.S. in Biophysics and a B.S. in Theoretical Physics. He has received many National awards from China in recognition of his accomplishments. Among them are the National Outstanding Achievement for Technology Development, 1988; Advanced Science and Technology Prize, 1986; National Great Achievement in Science and Technology, 1984. Dr. Chen brings to IQuum a wide assortment of disciplines as well as industrial and management experience. He has a proven record of overcoming many challenges using innovative means in both academia and industry. Dr. Chen has successfully developed medical devices for commercialization during his twenty years in blood research and medical device development.
Keith Greenfield is IQuum's co-founder, Board member, and Executive Vice President of Corporate Development. Mr. Greenfield is the Founder and President of The Dover Group, a privately held financial services firm in Wellesley, MA. He is also a cofounder of PreGreen Business Accelerator, which provides business development services for high-tech and biotechnology start-up ventures. Mr. Greenfield has helped found and serves on the board of several companies, including Biostream, US Biosystems, A.T.P. Therapeutics, Zebra Pharmaceuticals, Sight Code, Inc. InstrisiQ Data Corporation, and FoodSafe Solutions. Mr. Greenfield provides a depth of knowledge and experience in biotechnology entrepreneurship, team building and fund raising that has been essential to the company's successful launch.
Una S. Ryan, Ph.D. is President and CEO of AVANT Immunotherapeutics. She is also Research Professor of Medicine at the Whitaker Cardiovascular Institute of Boston University School of Medicine. Previously, Dr. Ryan held the position of Director of Health Sciences at Monsanto Company from 1990 to 1993 and was Research Professor of Surgery, Medicine and Cell Biology at Washington University School of Medicine from 1990 to 1993. Dr. Ryan currently serves on the boards of the Biotechnology Industry Organization and the Massachusetts Biotechnology Council.
Daniel J. Sutherby is IQuum’s Chief Financial Officer. He has over 22 years of broad experience in management positions at global companies operating in the medical device, health sciences, financial services and specialized manufacturing markets. From 2006 to 2008, Mr. Sutherby was employed as Chief Financial Officer, Chief Accounting Officer and Treasurer of Abiomed, Inc. From 1998 to 2005, Mr. Sutherby was employed by PerkinElmer, Inc. in a number of management positions, serving as Corporate Director of Global Accounting & Finance from 1998 to 2000, Director of Global Finance for PerkinElmer’s Life and Analytical Sciences Unit from 2001 to 2003, and Corporate Vice President of Investor Relations, Corporate Communications and Risk Management from 2003 to 2005. Mr. Sutherby is a Certified Public Accountant, and has a bachelor’s degree in accounting and a master of science degree in finance from Bentley University.
David A. Taft is the President of IBS Capital Corporation, an investment bank, which he founded in 1990. Mr. Taft manages the IBS Turnaround Fund, a private investment fund, which was recently recognized by Barron's for outstanding performance. Prior to founding IBS Capital Corporation, Mr. Taft spent ten years working in corporate finance with Drexel Burnham Lambert, Winthrop Financial and Merrill Lynch.
|
|